← Human Trials & Peer-Reviewed Studies
Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Plain-language guide to PMID 41276951 (2025): meta-analysis of Semaglutide and Glucagon, chronic and systemic inflammation.
Key Facts
- PMID
- 41276951
- Journal
- Endocrinology, diabetes & metabolism
- Year
- 2025
- Study type
- Meta-Analysis
- Authors
- Abdullah A et al. (14 authors)
- DOI
- 10.1002/edm2.70136
What This Paper Covers, in Plain Language
What It Covers
The paper reports a study of Semaglutide and Glucagon in the context of chronic and systemic inflammation, published as a meta-analysis.
This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability.
International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD420251019235.
Who the Included Studies Covered
Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included.
How the Review Was Done
MEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines.
Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke.
Risk of bias was assessed using Cochrane RoB 2.0.
What Was Measured
The subject headings attached to it are Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Hypoglycemic Agents, Cardiovascular Diseases, Glucagon-Like Peptide 1 and Semaglutide.
The authors tagged it with the keywords GLP‐1 receptor agonist, cardiovascular outcomes, chronic kidney disease, major adverse cardiovascular events, major kidney adverse events and meta‐analysis.
What This Means in Plain Language
This is a meta-analysis of Semaglutide and Glucagon in people with chronic and systemic inflammation.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (Endocrinology, diabetes & metabolism), a journal based in England.
More context: the Semaglutide compound page and the Glucagon compound page, Chronic and systemic inflammation research.
Our Notes on the Compounds
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.